[ Back to EurekAlert! ]

Contact: Mary Beth OLeary
moleary@cell.com
617-397-2802
Cell Press

Reassuring Evidence: Anticancer Drug Does not Accelerate Tumor Growth after Treatment Ends (2 of 2)

Caption: Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on Feb. 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

Credit: Cell Reports, Blagoev et al.

Usage Restrictions: Credit Required

Related news release: Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends


[ Back to EurekAlert! ]